NIKKEI 225
39,069.68 +282.30 (+0.73%) HANG SENG
19,652.94 +99.33 (+0.51%) CRUDE OIL
80.28 +0.22 (+0.27%) GOLD FUTURES
2,443.60 +26.20 (+1.08%) DOW
40,003.59 +134.19 (+0.34%) Bitcoin GBP
52,765.25 +21.52 (+0.04%)
DTIL Jun 2024 2.500 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 2.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 100 |
Business WirePrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., May 17, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on May 13, 2024, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement
Business WirePrecision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
DURHAM, N.C., May 13, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update.
Business WirePrecision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
DURHAM, N.C., May 08, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL) (the "Company"), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, today announced that it has entered into a definitive subscription agreement, pursuant to which the Company will issue and sell in a non-brokered private placement to members of its senior leadership team,
